You are here

BioVaxys Technology Corp.

BioVaxys Technology Corp.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
BIOV
CSE Index: 
Currency: 

BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.

You are here

BioVaxys Technology Corp. (BIOV)

SEDAR Information

Company Info

Address
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
Phone
646-452-7000
Email
[email protected]
Website
https://biovaxys.com/
Listing date
Wednesday, November 21, 2018
Transfer Agent
Odyssey Trust Company
Email
[email protected]
Auditor
Dale Matheson Carr-Hilton Labonte LLP

Capitalization

Issued & Outstanding: 
263922073
Reserved for Issuance: 
121251394

Company Officers

James Passin, CEO
Kenneth Kovan, COO & President
Christopher Cherry, Chief Financial Officer
James Passin, Chief Executive Officer
Christopher Cherry, Chief Financial Officer
Kenneth Kovan, Chief Operating Officer and President

Bulletins

16/07/2024

2024-0715 - Reinstatement - BioVaxys Technology Corp. (BIOV)

le 16 juillet/July 2024

Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.

The Company has rectified the situation that gave rise to the suspension.

____________________________

Avec effet immédiat, BioVaxys Technology Corp. sera réintégrée à la négociation.

La Société a rectifié la situation qui a donné lieu à la suspension.